QuidelOrtho director gains 6,829 shares via RSU vesting

QuidelOrtho Corp director Ann D. Rhoads reported equity compensation activity involving restricted stock units.

Rhea-AI Filing Summary

QuidelOrtho Corp director Ann D. Rhoads reported equity compensation activity involving restricted stock units. She received 6,829 shares of Common Stock at no cost, related to previously reported restricted stock units. These restricted stock units, each representing one share of common stock, vested on May 29, 2026 and were exercised into common shares the same day. Following these transactions, she holds 23,257 shares of QuidelOrtho common stock directly, with no remaining position in the exercised restricted stock units.

Insights

Equity compensation analyst

Routine RSU vesting and exercise, no share sale.

Director Ann D. Rhoads had 6,829 restricted stock units vest on May 29, 2026. These units were converted into an equal number of QuidelOrtho common shares at a price of $0.00 per share, indicating compensation rather than a market purchase.

The filing shows this as a grant/award acquisition and a derivative exercise, with no reported sales or tax-withholding dispositions. After the transactions, Rhoads holds 23,257 common shares directly. This pattern is typical of equity incentives vesting for board members and does not by itself signal a change in sentiment.

Insider Trade Summary

6,829 shares exercised/converted

Exercise 2 txns

Insider RHOADS ANN D

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units (Equity Grant)	6,829	$0.00	$0.00
Grant/Award	Common Stock	6,829	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units (Equity Grant) — 0 contracts (Direct); Common Stock — 23,257 shares (Direct)

Footnotes (3)

1. F1. Reflects release of restricted stock units that were previously reported on a Form 4.
2. F2. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
3. F3. The restricted stock units vested on May 29, 2026.

Key Figures

RSU shares vested: 6,829 shares Issue price per share: $0.00 per share Shares held after transaction: 23,257 shares +2 more

5 metrics

RSU shares vested 6,829 shares Restricted stock units converted to common stock on May 29, 2026

Issue price per share $0.00 per share Price for common shares received from RSU conversion

Shares held after transaction 23,257 shares Director’s direct common stock holdings following Form 4 transactions

RSUs remaining after exercise 0 units Previously reported RSUs that were fully exercised into common stock

Number of acquisition transactions 2 transactions One grant/award acquisition and one derivative exercise

Key Terms

Restricted Stock Units, derivative security, grant, award, or other acquisition, vested

4 terms

Restricted Stock Units financial

"Reflects release of restricted stock units that were previously reported on a Form 4."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

grant, award, or other acquisition financial

"Grant, award, or other acquisition"

vested financial

"The restricted stock units vested on May 29, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did QuidelOrtho (QDEL) director Ann D. Rhoads report in this Form 4?

Ann D. Rhoads reported equity compensation activity, including vesting and conversion of 6,829 restricted stock units into common stock. These transactions reflect routine director compensation rather than an open-market stock purchase or sale.

How many QuidelOrtho (QDEL) shares did Ann D. Rhoads acquire in this filing?

She acquired 6,829 shares of QuidelOrtho common stock when her restricted stock units vested and were converted. The shares were issued at a stated price of $0.00 per share as part of her equity compensation.

What are the restricted stock units reported by QuidelOrtho (QDEL) director Ann D. Rhoads?

The restricted stock units are equity awards where each unit represents the right to receive one QuidelOrtho common share. In this filing, 6,829 units vested and were converted into the same number of common shares for the director.

When did Ann D. Rhoads’ restricted stock units in QuidelOrtho (QDEL) vest?

Her restricted stock units vested on May 29, 2026. On that date, 6,829 units were released and converted into 6,829 shares of QuidelOrtho common stock as part of her director compensation program.

How many QuidelOrtho (QDEL) shares does Ann D. Rhoads hold after these transactions?

After the reported transactions, Ann D. Rhoads directly holds 23,257 shares of QuidelOrtho common stock. The exercised restricted stock units now have a zero remaining balance, indicating they were fully converted into shares.

Does this QuidelOrtho (QDEL) Form 4 show any stock sales by Ann D. Rhoads?

No, the Form 4 reports acquisitions from an equity award grant and the exercise of restricted stock units, with no sales or dispositions. The transactions represent compensation-related vesting rather than open-market selling activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RHOADS ANN D

(Last) (First) (Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		6,829(1)	A	$0	23,257	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (Equity Grant)	(2)	05/29/2026		M			6,829	(3)	(3)	Common Stock	6,829	$0	0	D

Explanation of Responses:

1. Reflects release of restricted stock units that were previously reported on a Form 4.

2. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

3. The restricted stock units vested on May 29, 2026.

Remarks:

	/s/ Phillip S. Askim, attorney-in-fact for Ann D. Rhoads	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)